Navigation Links
Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/4/2012

PHILADELPHIA, Sept. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics, will present at the Rodman & Renshaw Annual Global Investment Conference.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Dr. Mooney will make a corporate presentation to prospective corporate partners and investors at 3:15 PM ET on Tuesday, September 11th in New York City.  

At the time of the presentation, a live audio webcast, with slides, of Dr. Mooney's presentation will be available on the company's website at www.echotx.com.  The webcast will then be available for 90 days following the event.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                                          
Director, Investor Relations and Corporate Communications
colimpio@echotx.com
(215) 717-4104                                                                   

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
2. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Global Markets for Animal Therapeutics and Diagnostics
5. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
6. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
7. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
8. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
9. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
10. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
11. Nile Therapeutics Reports 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... Mo. , May 3, 2016 ... Medical Center,s Institute for Advancing Medical Innovation (IAMI) ... commercialize new drugs, diagnostics and medical devices. ... BioNovus Innovations with rights to license, develop and ... "This partnership represents a ...
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Momsense, ... nursing mothers. The company’s patented technology, The Smart Breastfeeding Meter, is designed to ... that the technology is now available for purchase at Target.com . ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen ... forever with a same-day LASIK procedure at Christenbury Eye Center. The entrepreneur ... Christenbury performed her surgery the same day as her in-office consultation and eye exam. ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare facility Pearl Recovery Retreat ... cancer surgery. In March 2016, the 61-year-old model and reality TV star was diagnosed ... in the milk ducts, according to an interview with the Daily Mail Online ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... coding, billing and compliance. In upcoming months, AudioEducator has lined up some informative ... conference is designed to give complete compliance know-how and practical, easy-to-apply advice. , ...
(Date:5/4/2016)... ... May 03, 2016 ... of innovative infant and child products, today revealed the non-toxic benefits ... to help babies deal with teething pain is just part of ... toxic gels, and are BPA-, PVC-, and phthalate-free. , “Many ...
Breaking Medicine News(10 mins):